Aurinia Pharmaceuticals (AUPH) Posts Wider Q2 Loss

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of ($0.26), $0.12 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $29 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• AutoZone (AZO) Tops Q4 EPS by $1.76, Misses on Revenue
• H.C. Wainwright Reiterates Buy Rating on AnaptysBio (ANAB)